250results about "Antiparasitic agents" patented technology

The application discloses a new Bartonella species DGB1 derived from chicken skin mite and application of the Bartonella species DGB1 in prevention and treatment of chicken skin mite. Bartonella sp. The application provides a new Bartonella species, specifically a Bartonella DGB1, which is registered and listed in the China General Microbiological Culture Collection Center with a registration number of CGMCC No. 36714. The application also provides a Bartonella inactivated bacteria solution and an inactivated vaccine prepared from the Bartonella. The Bartonella inactivated vaccine provided by the application can effectively prevent and control chicken skin mite.

The application discloses a sweet wormwood extract, a preparation method and application thereof and a sweet wormwood extract veterinary drug, and the method comprises the following steps: S1, heating and extracting sweet wormwood byproducts with an extraction solvent, filtering, discarding the filtrate, and obtaining an intermediate product filter cake; S2, concentrating the intermediate product filter cake to a constant weight; S3, heating and extracting the constant weight obtained in the step S2 with deionized water, filtering, and taking the filtrate; S4, concentrating the filtrate obtained in the step S3 to a constant weight, and obtaining the sweet wormwood extract. The application provides a sweet wormwood extract and a preparation method thereof, and provides a veterinary drug based on the sweet wormwood extract; the veterinary drug obtained by the application can clear heat, resolve summer-heat, and relieve deficiency heat, and can be used for treating various livestock and poultry diseases; the preparation method is simple, easy to operate, raw materials are easy to obtain, production cost is low, and the application has a good market application prospect.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The application belongs to the technical field of pesticides, and particularly relates to a fused heterocyclic compound, a preparation method, an insecticidal composition and application thereof. The compound is shown in the general formula I: wherein X represents R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 respectively independently represent hydrogen, halogen, alkyl, alkenyl and the like; the compound has excellent control effects on Spodoptera exigua, Mythimna separata, Helicoverpa armigera and the like.

This application relates to the field of veterinary drug technology, and discloses a transdermal absorption-enhancing ointment and its preparation process. The ointment components include white petrolatum, anhydrous lanolin, caprylic / capric triglycerides, hydrophobic fumed silica, and a highly fluid active permeation-enhancing phase. The permeation-enhancing phase contains active drugs and soybean lecithin, which self-assemble to form an inverse micelle aggregate. Soybean lecithin cross-links with the silanol groups on the surface of silica to form an intermolecular hydrogen bond network, constructing a sterically hindered framework within a continuous lipid matrix to prevent the polar drug-loaded phase from permeating and separating upon heating. Simultaneously, the inverse micelle structure effectively improves the transdermal absorption rate of the drug. The preparation process controls the lipid crystallization kinetics through slow cooling under negative pressure and micro-shear dynamic rheology. This invention solves the problems of easy precipitation upon heating, low transdermal efficiency, and poor rheological properties in traditional ointments, resulting in a product with a stable physical structure and good pseudoplastic texture.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present application relates to a preparation of a coumarin-phenylpropanoid polymer 5'-demethoxydaphnodorin and its application in preparing anti-malaria products, and belongs to the field of traditional Chinese medicine and natural medicine pharmacy. The anti-malaria medicine with the compound 5'-demethoxydaphnodorin as an active ingredient. The present application expands the medicinal value of the coumarin-phenylpropanoid polymer in southwest hydrangea.

The application provides application of Bacteroides fragilis in improving and / or treating diarrhea. It is proved by different mouse diarrhea model tests that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No. 10685 or inactivated bacteria thereof have the effects of improving and treating diarrhea. The inactivated bacteria powder of the Bacteroides fragilis has better effects on improving infectious diarrhea or non-infectious diarrhea under different concentration formulations, has no side effects on the body, has a good edible and application prospect, and provides a good product suitable for human consumption for health care and improvement of diarrhea.

The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.

Suspensions of metronidazole or baclofen and / or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension may include metronidazole or baclofen, and / or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

This invention belongs to the field of organic synthetic chemistry technology, specifically relating to a selenium-based indoloquinazoline derivative, its preparation method, and its application, comprising: in an organic solvent, using aromatic amine compounds, malononitrile, and diselenoether as raw materials, in the presence of a palladium catalyst and an organic base, at 90°C... o The reaction was carried out under C conditions with stirring to obtain a selenyl indoline quinazoline derivative. This method features mild reaction conditions, simple operation, high yield, and good functional group compatibility, conforming to the principles of green chemistry. Furthermore, the selenyl indoline quinazoline derivative provided by this invention exhibits good inhibitory activity against Plasmodium, providing a drug lead compound for the development of novel antimalarial drugs and holding significant importance for the prevention and / or treatment of malaria.

The present invention relates to a package for storing a sterile pharmaceutical composition, comprising at least an inner layer of polypropylene having a thickness of 200 to 800 μm and an outer layer made of polyethylene, the outer layer being in contact with the environment and having a thickness of 300 to 1000 μm. The present invention also relates to a method for the sterile storage of a pharmaceutical composition using such a package.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

Provided herein are endochin-like quinolone (ELQ) compounds of formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them, and methods for their use in the treatment or prevention of parasitic diseases including malaria, toxoplasmosis, and babesiosis. TIFF2025524371000356.tif48128

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating vaginitis, and preparation raw materials of the traditional Chinese medicine composition include zedoary turmeric and Chinese atractylodes rhizome. The traditional Chinese medicine composition can kill common pathogenic bacteria of vaginosis, and has good bacteriostatic effect. While inhibiting the common pathogenic bacteria of vaginosis, the traditional Chinese medicine composition does not inhibit lactobacillus of vagina. The traditional Chinese medicine composition can not only kill single common pathogenic bacteria of vaginosis, but also relieve trichomonas vaginalis, and inhibit mixed infection of bacteria and fungi.

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and / or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.

The present application provides a kind of isoxazoline thiofene compound and its application, the isoxazoline compound has the structure as shown in formula I, the compound of the present application can be used to prevent and treat parasitic infection, has good prevention and treatment effect, shows good pharmacokinetic properties in mouse in vivo.

The application discloses a saliva gland protein of Rhipicephalus sanguineus and application thereof, and belongs to the technical field of tick prevention and control. In order to provide a saliva gland protein vaccine of Rhipicephalus sanguineus which can be used for prevention and control of ticks and tick-borne diseases. The application provides the saliva gland protein of Rhipicephalus sanguineus, and the amino acid sequence of the protein is shown as SEQ ID NO. 1. A medicine and a vaccine for effectively preventing and controlling Rhipicephalus sanguineus are prepared.

Imidazoquinoline compounds are described that have activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer.

The application provides an application of MTOR in preparation of a drug for treating congenital toxoplasmosis, relates to the biomedical technical field, and proves through specific examples in the application that MTOR is highly expressed in mouse placental tissue in an animal model such as congenital toxoplasmosis. Meanwhile, TgAg promotes the expression of the MTOR protein of macrophages. The use of an MTOR inhibitor can significantly improve congenital toxoplasmosis. Through the verification experiment of the embodiment, it can be seen that Toxoplasma gondii and its antigen promote the expression of MTOR. The effect of the MTOR inhibitor in significantly improving congenital toxoplasmosis is verified. Therefore, a new direction and a drug for treating congenital toxoplasmosis are provided.

This invention discloses an isoxazoline compound and its application, belonging to the field of sanitary and agricultural insecticide technology. The isoxazoline compound is shown in Formula I: I; where: R1 represents a substituent on the benzene ring, selected from monosubstituted or polysubstituted groups; when R1 is polysubstituted, the multiple substituents may be the same or different; R1 is selected from one or more of hydrogen, chlorine, fluorine, and trifluoromethyl; R2 is selected from C 1‑6 Straight-chain or branched alkyl groups, C 1‑6 Straight-chain or branched fluoroalkyl, C 3‑6 cycloalkyl, C 3‑6 The isoxazoline compound provided in this application is one of the following: fluorocycloalkyl, N-alkylamide with 1-3 carbon atoms, or N-fluoroalkylamide. It exhibits high insecticidal activity, rapid onset of action, and long duration of action, demonstrating excellent biological activity in killing parasites. It can be used for the prevention and treatment of parasitic infections and invasions, and has broad clinical application prospects and market promotion value.

The application relates to an anti-parasite composition and application thereof, and the anti-parasite composition comprises the following components in mass percentage (w / v): 6-10% of non-pyrantel, 6-10% of pyrantel, 0.5-2% of moxidectin, 8-12% of methoprene, 0.1-0.3% of an antioxidant, 3-5% of a skin protective agent and the balance of a solvent, wherein the antioxidant is dibutylhydroxytoluene and tea polyphenol. The anti-parasite composition disclosed by the application has a wide parasite expelling spectrum, is mild, stable and long-acting, and can expel internal and external parasites.

This invention provides a class of general-purpose chiral catalysts containing a cinchona primary amine arylformamide skeleton, along with their preparation methods and applications, belonging to the field of catalytic materials technology. The chiral catalysts provided by this invention link cinchona primary amine with oxazole / thiazole / imidazolium formamide structural units capable of coordination. Through the coordination of the oxazole / thiazole / imidazolium and amide coordinating groups with the central metal, they act as chiral ligands to catalyze a wider range of asymmetric reactions. They can also be used alone as chiral small-molecule catalysts for cinchona-like tertiary amine (thiourea) and square amides to catalyze asymmetric organic reactions. Furthermore, they can achieve synergistic (co-catalytic) catalysis of small molecules and metals in the same reaction system through different combinations. These chiral catalysts can be widely used as Lewis bases, Lewis acids, or small-molecule chiral catalysts and chiral ligands, possessing potential scientific and applied value in chiral sciences such as asymmetric catalysis, chiral synthesis, and chiral resolution.

Disclosed are GLO2 and its use in promoting or inhibiting inflammatory or immune responses. The use of a nucleic acid encoding GLO2, a GLO2 protein, or a promoter of GLO2 in the preparation of a medicament for promoting an inflammatory or immune response, the use of an inhibitor of GLO2 in the preparation of a medicament for inhibiting an inflammatory or immune response, and the use of a detection agent of GLO2 in the preparation of a kit for screening a medicament and / or therapy for an inflammatory or immune response are involved.

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.